What Sen-Jam Pharmaceutical does

Sen-Jam Pharmaceutical is a clinical-stage, computational drug discovery and development company founded in 2014 and headquartered at 223 Wall Street #130, Huntington, NY. The company develops prevention-led combination anti-inflammatory therapeutics targeting large unmet needs across hangover prevention, COVID-19, viral respiratory infections, vaccine side effects, arthritis, opioid use disorder (withdrawal, dependence, and tolerance), metabolic health (MASH/obesity), critical care inflammatory rescue, and longevity/inflammaging. Its pipeline spans more than ten candidates (SJP-001 through SJP-007, plus SJP-100, SJP-200, SJP-101, SJP-002X, and SJP-001X), with lead asset SJP-001 (alcohol hangover prevention, OTC) Phase 3 ready and SJP-002C (COVID-19 treatment, Rx) in Phase II trials.

The company operates through its proprietary Inflammation Atlas platform, an AI-driven Quantitative Systems Pharmaco-Biology engine that maps inflammatory architecture, models feedforward inflammatory loops, identifies molecular nodes, and predicts combination therapeutics. Combinations use AI-matched, already FDA-cleared small molecules with complementary, non-redundant pathway activity targeting COX-Prostaglandin and Histamine/Mast Cell/Adaptive Immune loops, intended to lower regulatory risk by repurposing approved agents. A cross-program NLR (Neutrophil-to-Lymphocyte Ratio) biomarker patent has been filed and validated across two independent Phase 2 datasets, with reported outcomes including a 76% reduction in headache severity and near-complete symptom resolution for SJP-001, and complete symptom clearance by Day 15 for SJP-002C.

Sen-Jam is pre-revenue with a 1-10 person team and pursues a dual-track go-to-market: enterprise out-licensing and co-development partnerships with pharmaceutical companies for global commercialization upon regulatory approval, plus future OTC distribution for consumer products such as SJP-001 and SJP-003. Capital has been raised via equity crowdfunding on StartEngine (approximately $1.0M in 2021 and ~$297K Series A in 2022), a 2025 strategic investment from 5 Horizons Capital, and a notable CRO equity arrangement with TASK Clinical funding two-thirds of the SJP-001 Phase 3 trial. Operational geographies span the US (headquarters), Australia (Novotech-led Phase 2), and Canada (Cliantha Research Phase 2), with clinical and CMC execution supported by partners TASK Clinical, KVK Tech, Cliantha Research, and Novotech.

Name

Sen-Jam Pharmaceutical

Legal name

Sen-Jam Pharmaceutical

Website

https://sen-jam.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Sen-Jam Pharmaceutical is a clinical-stage drug discovery company using its proprietary Inflammation Atlas AI platform to develop combination anti-inflammatory therapeutics. Its pipeline includes a Phase 3-ready hangover prevention OTC, a Phase II COVID-19 treatment, and opioid, metabolic, and longevity programs.

Ownership category

akta.pro rank

Product category

Anti-Inflammatory Pharmaceuticals

NAICS

Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Anti-inflammatory therapeutics
• Computational drug discovery
• Combination drug therapy
• Clinical stage biopharmaceutical
• Inflammation drug pipeline

Headquarters

HQ city

Huntington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Equity Funding / Crowdfunding: The company launched a Series A funding round through the StartEngine crowdfunding platform, engaging private and institutional investors to support drug portfolio advancement. The company has also secured strategic investments from financial partners including 5 Horizons Capital and equity arrangements with CRO partners.
2. Licensing Royalties: Revenue expected from licensing deals for drug candidates upon successful clinical trials and regulatory approvals. The company is building toward global licensing discussions ahead of pivotal Phase 3 programs.
3. Pharmaceutical Product Sales (Future): Once products receive regulatory approval, revenue anticipated from OTC and prescription pharmaceutical product sales including SJP-001 (hangover), SJP-002C (COVID), and pipeline assets for opioid addiction, arthritis, and metabolic health.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Sen-Jam Pharmaceutical develops a portfolio of combination therapeutic drug candidates for inflammatory conditions, generated through its proprietary AI-driven Inflammation Atlas platform. Its lead asset, SJP-001 (hangover prevention), is Phase 3 ready with a 76% reduction in headache severity demonstrated in clinical studies; SJP-002C (COVID-19 treatment) is in Phase II; additional pipeline assets address viral respiratory infections, vaccine side effects, arthritis, opioid withdrawal/dependence/tolerance, metabolic health, MASH, critical care inflammation, longevity, and enteropathic arthritis.

Product overview

Sen-Jam Pharmaceutical is a computational drug discovery and development company pioneering a prevention-led therapeutic platform focused on inflammatory resolution. The company operates through its proprietary Inflammation Atlas—an AI-driven systems biology engine that maps inflammatory architecture and generates combination therapeutics. The core portfolio includes multiple clinical-stage and preclinical drug candidates across therapeutic areas: SJP-001 (alcohol hangover prevention, Phase 3 ready, OTC), SJP-002C (COVID-19 treatment, Phase II, Rx), SJP-002 (viral respiratory infections, OTC), SJP-003 (vaccine side effects), SJP-004 (arthritis, Rx), SJP-005/006/007 (opioid use disorder addressing withdrawal, dependence, and tolerance respectively, Rx), plus pipeline assets including SJP-100 (critical care injectable), SJP-002X/001X (metabolic health), SJP-200 (longevity), and SJP-101 (enteropathic arthritis). The company emphasizes earlier intervention through immune balance restoration without immunosuppression, with clinical validation demonstrated across two independent Phase 2 programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Inflammation Atlas Proprietary AI-driven Quantitative Systems Pharmaco-Biology engine that maps human inflammatory architecture, models feedforward inflammatory loops, identifies molecular nodes driving them, and predicts combination therapeutics designed for earlier, safer, and more complete inflammatory resolution. Used internally to generate Sen-Jam's SJP pipeline candidates.
• SJP-001 (Alcohol Hangover Prevention) Over-the-counter oral combination therapeutic targeting COX-Prostaglandin and Histamine loops for prevention of alcohol hangover (veisalgia). Phase 3 ready with 76% reduction in headache severity and near-complete symptom resolution demonstrated in human studies; positioned as the only FDA-approved agent in development for this indication.
• SJP-002C (COVID-19 Treatment) Prescription-strength oral anti-inflammatory therapeutic for treatment of SARS-CoV-2 infection, targeting COX-Prostaglandin, Mast Cell, and Adaptive Immune loops. In Phase II clinical trials with complete symptom clearance by Day 15 and selective immune rebalancing demonstrated.
• SJP-002 (Viral Respiratory Infections, OTC) Over-the-counter oral therapeutic for symptoms associated with viral respiratory infections including coronaviruses and the common cold, reducing excessive inflammatory response that causes congestion, coughing, sneezing, and headache.
• SJP-003 (Vaccine Side-Effect Reduction) Over-the-counter oral therapeutic administered at the time of vaccination to reduce or eliminate common vaccine administration side effects such as sore arm and low-grade fever.
• SJP-004 (Arthritis) Prescription-strength oral therapeutic designed to address inflammation and aches associated with arthritis without the side-effect profile of opioid-based agents.
• SJP-005 (Opioid Withdrawal) Prescription-strength oral therapeutic for opioid use disorder that reduces signs and symptoms of withdrawal by 50% in pre-clinical studies, addressing a critical factor in combating the opioid epidemic.
• SJP-006 (Opioid Dependence) Prescription-strength oral therapeutic designed to address opioid dependence, making tapering off opioid pain killers more readily available for the millions of patients prescribed opioids each year.
• SJP-007 (Opioid Tolerance) Prescription-strength oral therapeutic that helps lower individual tolerance factors to opioids including OxyContin, morphine, oxycodone, and heroin, supporting reversal of opioid dependence.
• SJP-100 (Inflammatory Rescue Program) Prescription-strength injectable therapeutic for inflammatory rescue programs in critical care settings.
• SJP-002X (Obesity / MASH) Prescription-strength oral therapeutic targeting obesity and MASH (Metabolic dysfunction-associated steatohepatitis) for metabolic health.
• SJP-001X (Metabolic Recovery) Over-the-counter oral therapeutic for metabolic recovery targeting metabolic health and weight management.
• SJP-200 (Healthy Aging / Longevity) Prescription-strength oral therapeutic targeting inflammaging and low-grade chronic inflammatory conditions associated with healthy aging and longevity.
• SJP-101 (Enteropathic Arthritis) Prescription-strength injectable therapeutic for enteropathic arthritis, a chronic inflammatory disease.

Quantifiable outcome

• 76% reduction in headache severity with SJP-001
• +5 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• TASK ClinicalcoreStrategic or Co-development PartnerStrategic partnership with TASK Clinical, a global contract research organization (CRO), under which TASK Clinical will fund two-thirds of the upcoming Phase 3 clinical trial for SJP-001 in exchange for equity. This rare arrangement where a CRO takes an equity position in sponsor trials significantly de-risks the pivotal program and strengthens investor confidence and licensing opportunities.
• KVK TechcoreStrategic or Co-development PartnerCorporate venture partner handling formulation, CMC (Chemistry, Manufacturing and Controls), and FDA submission readiness. Forms part of the vertically integrated development ecosystem for Sen-Jam's drug candidates.
• NovotechcoreStrategic or Co-development PartnerClinical CRO with expertise in early-phase trials, conducting Phase 2 trial of SJP-001 with ethics approval obtained in Australia. Partnership aims to advance development and potential global adoption.
• Cliantha ResearchcoreStrategic or Co-development PartnerPhase 2 trial conducted by Cliantha Research in Toronto, completed in November with data readout expected in Q1 2026.
• Rute FernandesminorOthersAppointed as Executive Advisor to support commercialization strategy and pipeline development, guiding strategic planning, partner exploration, and launch preparedness for anti-inflammatory therapeutics.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Schrödinger, Inc. Computational drug discovery platform company combining physics-based simulation with AI for therapeutic discovery across multiple partners. Comparable through its AI/computational platform approach to inflammatory and other targets, though substantially larger and software-plus-collaboration oriented.

Direct peers

• Landos Biopharma: Clinical-stage biotech developing oral therapeutics for inflammatory and autoimmune diseases (ulcerative colitis, Crohn's). Comparable as a clinical-stage inflammation company with a similar small-team, outsourced-execution model and reliance on licensing for global commercialization.
• Recursion Pharmaceuticals: Clinical-stage AI-driven drug discovery company combining computational biology with experimental validation across multiple therapeutic areas. Highly comparable to Sen-Jam's Inflammation Atlas platform approach and pipeline breadth, though operating at significantly larger scale and capital base.
• Axsome Therapeutics: Clinical-stage CNS-focused biotech developing anti-inflammatory and novel mechanism therapeutics (e.g., Auvelity for depression, migraine products). Comparable as a small-cap, clinical-stage inflammation/CNS company pursuing differentiated mechanisms with similar regulatory and licensing pathway dynamics.
• Morphic Holding: Clinical-stage biotech developing oral integrin inhibitors for inflammatory and autoimmune diseases. Comparable as a clinical-stage inflammation company pursuing differentiated oral small-molecule approaches with similar regulatory and competitive dynamics.
• Aclaris Therapeutics: Clinical-stage biotech developing novel therapeutics for inflammatory and immunological diseases, including dermatology indications. Comparable in therapeutic area overlap (inflammation) and stage profile, with similar strategic optionality around licensing and combination development.
• BioAge Labs: Clinical-stage biotech developing therapeutics targeting the biology of aging, including metabolic and inflammatory pathways. Closely comparable in the inflammaging/longevity space Sen-Jam targets via SJP-200 and SJP-001X/002X, with similar capital needs and clinical-stage profile.
• Keros Therapeutics: Clinical-stage biotech developing transformative treatments for hematological and musculoskeletal disorders with inflammatory drivers. Comparable as a small-cap clinical-stage inflammation/biologics company with similar capital needs and licensing-driven business model.
• Pliant Therapeutics: Clinical-stage biotech developing novel therapies for fibrotic and inflammatory diseases using integrin-based mechanisms. Comparable as a clinical-stage inflammation company with multiple pipeline assets and similar strategic positioning for licensing transactions.

Emerging players

• Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology to develop therapeutics. Comparable through its computational platform approach to inflammatory and metabolic diseases, though operating at a larger capital base and more diverse partnership model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/senjampharma
• Facebookfacebook.com/senjampharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sen-Jam Pharmaceutical